Beamion Lung 1, an ongoing phase Ia/Ib trial of the HER2 TKI, BI 1810631 in patients (pts) with advanced solid tumors with HER2 aberrations: Latest data

被引：2
|
作者：
Opdam, F. [1 ]
Heymach, J. [2 ]
Ruiter, G. [3 ]
Barve, M. [4 ]
Tu, H. [5 ]
Wu, Y-L. [5 ]
Schroeter, L. [6 ]
Sadrolhefazi, B. [7 ]
Serra, J. [8 ]
Yoh, K. [9 ]
Yamamoto, N. [10 ]
机构：
[1] Netherlands Canc Inst, Dept Clin Pharmacol, Amsterdam, Netherlands
[2] Univ Texas Houston, Div Canc Med, Dept Thorac Head & Neck Med Oncol, MD Anderson Canc Ctr, Houston, TX USA
[3] Netherlands Canc Inst, Antoni van Leeuwenhoek Hosp, Thorac Oncol & Phase 1 Studies, NKI AVL, Amsterdam, Netherlands
[4] Mary Crowley Canc Res Ctr, Dallas, TX USA
[5] Southern Med Univ, Guangdong Lung Canc Inst, Guangdong Prov Peoples Hosp, Guangdong Acad Med Sci, Guangzhou, Peoples R China
[6] Boehringer Ingelheim Pharma GmbH & Co KG, Biostat & Data Sci, Biberach, Germany
[7] Boehringer Ingelheim Pharmaceut Inc, Oncol, Ridgefield, CT USA
[8] Boehringer Ingelheim SA, CD&O, Sant Cugat Del Valles, Spain
[9] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[10] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2408
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1375P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Sarina A. Piha-Paul
    Analía Azaro
    Hendrik Tobias Arkenau
    Do-Youn Oh
    Matthew D. Galsky
    Sumanta Kumar Pal
    Kensuke Hamada
    Yaohua He
    Ikuo Yamamiya
    Karim A Benhadji
    Antoine Hollebecque
    Investigational New Drugs, 2021, 39 : 1324 - 1334
  • [22] A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations
    Piha-Paul, Sarina A.
    Azaro, Analia
    Arkenau, Hendrik Tobias
    Oh, Do-Youn
    Galsky, Matthew D.
    Pal, Sumanta Kumar
    Hamada, Kensuke
    He, Yaohua
    Yamamiya, Ikuo
    Benhadji, Karim A.
    Hollebecque, Antoine
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (05) : 1324 - 1334
  • [23] Open-label, dose-escalation phase 1a study of SPH5030, a tyrosine kinase inhibitor (TKI) targeting HER2, in patients with HER2 positive advanced solid tumors
    Wang, Jiayu
    Wang, Wenna
    Tong, Zhongsheng
    Shi, Yehui
    Shi, Yanxia
    Zheng, Qiufan
    Yu, Shunjiang
    Cao, Yuanyuan
    Xie, Ning
    Fan, Jianru
    Xu, Binghe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers
    Wilding, Birgit
    Woelflingseder, Lydia
    Baum, Anke
    Chylinski, Krzysztof
    Vainorius, Gintautas
    Gibson, Neil
    Waizenegger, Irene C.
    Gerlach, Daniel
    Augsten, Martin
    Spreitzer, Fiona
    Shirai, Yukina
    Ikegami, Masachika
    Tilandyova, Sylvia
    Scharn, Dirk
    Pearson, Mark A.
    Popow, Johannes
    Obenauf, Anna C.
    Yamamoto, Noboru
    Kondo, Shunsuke
    Opdam, Frans L.
    Bruining, Annemarie
    Kohsaka, Shinji
    Kraut, Norbert
    Heymach, John V.
    Solca, Flavio
    Neumueller, Ralph A.
    CANCER DISCOVERY, 2025, 15 (01) : 119 - 138
  • [25] Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
    Yap, Timothy A.
    Vidal, Laura
    Adam, Jan
    Stephens, Peter
    Spicer, James
    Shaw, Heather
    Ang, Jooern
    Temple, Graham
    Bell, Susan
    Shahidi, Mehdi
    Uttenreuther-Fischer, Martina
    Stopfer, Peter
    Futreal, Andrew
    Calvert, Hilary
    de Bono, Johann S.
    Plummer, Ruth
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3965 - 3972
  • [26] A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours
    G Attard
    J Kitzen
    S P Blagden
    P C Fong
    L C Pronk
    J Zhi
    G Zugmaier
    J Verweij
    J S de Bono
    M de Jonge
    British Journal of Cancer, 2007, 97 : 1338 - 1343
  • [27] A PHASE 1 STUDY OF MM-111; A BISPECIFIC HER2/HER3 ANTIBODY FUSION PROTEIN, COMBINED WITH MULTIPLE TREATMENT REGIMENS IN PATIENTS WITH ADVANCED HER2 POSITIVE SOLID TUMORS
    Richards, D.
    Braiteh, F.
    Anthony, S.
    Edenfield, W.
    Hellerstedt, B.
    Raju, R.
    Conkling, P.
    McDonagh, C.
    Frye, S.
    Moyo, V.
    ANNALS OF ONCOLOGY, 2012, 23 : 170 - 170
  • [28] Zongertinib (BI1810631), an irreversible HER2 TKI spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers
    Neumueller, R.
    Wilding, B.
    Augsten, M.
    Baum, A.
    Chylinski, K.
    Waizenegger, I.
    Woelflingseder, L.
    Solca, F.
    Kraut, N.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S56 - S56
  • [29] Phase II trial evaluating HER2 targeted activated T cells in advanced HER2 low expressing breast cancer patients
    Jagtap, Deepa Bai
    Thakur, Archana
    Deol, Abhinav
    Al-Kadhimi, Zaid
    Simon, Michael S.
    Flaherty, Lawrence E.
    Shields, Anthony Frank
    Schalk, Dana
    Paul, Elyse
    Kondadasula, Vidya
    Liu, Qin
    Lum, Lawrence G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy
    Osumi, H.
    Wakatsuki, T.
    Yamamoto, N.
    Ooki, A.
    Chin, K.
    Shoji, H.
    Ogura, M.
    Nakayama, I.
    Hirano, H.
    Hara, H.
    Minashi, K.
    Shinozaki, E.
    Kato, K.
    Kitano, S.
    Takeuchi, K.
    Boku, N.
    Yamaguchi, K.
    Takahari, D.
    ANNALS OF ONCOLOGY, 2024, 35 : S897 - S897
12345